CaGA nanozymes inhibit oxidative stress and protect mitochondrial function in ulcerative colitis therapy
Source abstract
Abstract
Ulcerative colitis (UC) is a long-term inflammatory bowel disease characterized by intense inflammation of the colorectal mucosa. Overproduction of reactive oxygen species exacerbates the progression of UC, which is linked to mitochondrial impairment and dysbiosis of the intestinal microbiota. CaGA nanozymes have demonstrated efficacy in the treatment of UC. The modulation of M1 and M2 polarization of macrophages by CaGA nanozymes has been demonstrated to be useful in reducing inflammation. Furthermore, CaGA nanozymes regulate the M1 and M2 polarization of macrophages, efficiently decreasing inflammation. The oral delivery of CaGA nanozymes resulted in their enrichment in inflamed areas of the colon and effectively reduced colonic damage in mice with DSS-induced colitis by improving the repair of the intestinal barrier. An investigation of 16S rDNA sequencing revealed that CaGA nanozymes regulate populations of both pathogenic and helpful bacteria and impact the progression of ulcerative colitis by influencing the tricarboxylic acid (TCA) cycle. Thus, CaGA nanozymes may be employed in the management of ulcerative colitis to control the intestinal milieu and improve the preservation of the intestinal barrier by decreasing the invasion of inflammatory cells and restoring mitochondrial activity. STATEMENT OF SIGNIFICANCE: CaGA nanozymes exhibit multifunctional enzymatic activity, effectively eliminating cellular RONS with robust antioxidant capacity. CaGA nanoenzymes promote macrophage M1 to M2 polarization and produce anti-inflammatory effects. CaGA nanozymes increase cell viability by restoring impaired mitochondrial function, reducing reactive oxygen species (ROS) production, and restoring the ability of mitochondria to produce ATP. CaGA nanozymes modulate intestinal flora diversity and composition, potentially influencing inflammatory pathways via aromatic compound metabolism. They participate in cellular energy and biosynthesis, regulating ulcerative colitis (UC)-related intestinal function through the tricarboxylic acid (TCA) and urea cycles. Calcium ions bind to GA nanomedicine and small particles are readily absorbed by inflammatory cells, preventing diarrhea from being rapidly excreted.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Definition of mild to moderate ulcerative colitis in clinical trials: a systematic literature review10.1002/ueg2.12283 ↗
2. An oral pH-activated "nano-bomb" carrier combined with berberine by regulating gene silencing and gut microbiota for site-specific treatment of ulcerative colitis10.1039/D1BM01765A ↗
3. Ulcerative colitis10.1038/s41572-020-0205-x ↗
4. The metabolic nature of inflammatory bowel diseases10.1038/s41575-022-00658-y ↗
5. Versatile carbon dots with superoxide dismutase-like nanozyme activity and red fluorescence for inflammatory bowel disease therapeutics10.1016/j.carbon.2023.01.006 ↗
6. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles10.1016/j.biomaterials.2015.01.014 ↗
7. Design of diselenide-bridged hyaluronic acid nano-antioxidant for efficient ROS scavenging to relieve colitis10.1021/acsnano.2c05558 ↗
8. Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses10.1016/j.ymthe.2023.02.017 ↗
9. Ultrasmall rhodium nanozyme with RONS scavenging and photothermal activities for anti-inflammation and antitumor theranostics of colon diseases10.1021/acs.nanolett.9b05035 ↗
10. In situ-activated photothermal nanoplatform for on-demand NO gas delivery and enhanced colorectal cancer treatment10.1016/j.jconrel.2023.05.034 ↗
11. Metal polyphenol network/cerium oxide artificial enzymes therapeutic nanoplatform for MRI/CT-aided intestinal inflammation management10.1016/j.nantod.2023.102044 ↗
12. CuCo(2)O(4) nanoflowers with multiple enzyme activities for treating bacterium-infected wounds via cuproptosis-like death10.1021/acsnano.4c02825 ↗
13. Recent formulation approaches to oral delivery of herbal medicines10.1007/s40005-018-0394-4 ↗
14. Oral nanotherapeutics of andrographolide/carbon monoxide donor for synergistically anti-inflammatory and pro-resolving treatment of ulcerative colitis10.1021/acsami.3c09342 ↗
15. Ultrathin hafnium disulfide atomic crystals with ROS-scavenging and colon-targeting capabilities for inflammatory bowel disease treatment10.1021/acsnano.2c06151 ↗
16. Oral zero-valent-molybdenum nanodots for inflammatory bowel disease therapy10.1126/sciadv.abp9882 ↗
17. Reactive oxygen species-responsive polymeric nanoparticles for alleviating sepsis-induced acute liver injury in mice10.1016/j.biomaterials.2017.08.008 ↗
18. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury10.7150/thno.40395 ↗
19. Nanodot-doped peptide hydrogels for antibacterial phototherapy and wound healing10.1039/D1BM01533H ↗
20. Endogenous copper for nanocatalytic oxidative damage and self-protection pathway breakage of cancer10.1021/acsnano.1c05451 ↗
21. Depletable peroxidase-like activity of Fe(3)O(4) nanozymes accompanied with separate migration of electrons and iron ions10.1038/s41467-022-33098-y ↗
22. Copper-based nanomaterials for the treatment of bacteria-infected wounds: material classification, strategies and mechanisms10.1016/j.ccr.2024.216205 ↗
23. Gallic acid improved inflammation via NF-κb pathway in TNBS-induced ulcerative colitis10.1016/j.intimp.2018.11.049 ↗
24. Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review10.1007/s11011-019-00400-9 ↗
25. Regulation of Ca2+ exchanges and signaling in mitochondria10.1016/j.cophys.2020.08.010 ↗
26. Phosphorylation of neurogranin, protein kinase C, and Ca2+/calmodulin dependent protein kinase II in opioid tolerance and dependence10.1016/j.neulet.2006.06.013 ↗
27. Does dietary calcium interact with dietary fiber against colorectal cancer? A case-control study in Central Europe10.1186/1475-2891-12-134 ↗
28. Colon cancer and dietary fat, phosphate, and calcium: a hypothesis
29. Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium10.1093/carcin/4.9.1205 ↗
30. Enzyme-like biomimetic oral-agent enabling modulating gut microbiota and restoring redox homeostasis to treat inflammatory bowel disease
31. A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation10.7150/thno.43108 ↗
32. Mucosal immunity-mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer's patches10.1126/sciadv.abf0677 ↗
33. Oral nano-antioxidants improve sleep by restoring intestinal barrier integrity and preventing systemic inflammation10.1093/nsr/nwad309 ↗
34. Biological drug and drug delivery-mediated immunotherapy10.1016/j.apsb.2020.12.018 ↗
35. Hydrogen peroxide responsive covalent cyclodextrin framework for targeted therapy of inflammatory bowel disease10.1016/j.carbpol.2022.119252 ↗
36. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease10.1016/j.biomaterials.2016.08.010 ↗
37. Modified Gegen Qinlian decoction ameliorated ulcerative colitis by attenuating inflammation and oxidative stress and enhancing intestinal barrier function in vivo and in vitro10.1016/j.jep.2023.116538 ↗
38. TKT maintains intestinal ATP production and inhibits apoptosis-induced colitis10.1038/s41419-021-04142-4 ↗
39. Paracellular permeability and tight junction regulation in gut health and disease10.1038/s41575-023-00766-3 ↗
40. Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-κb pathway quenches intestinal inflammation and oxidative stress injury10.1016/j.ebiom.2018.08.035 ↗
41. Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation10.1016/j.apsb.2021.03.011 ↗
42. Hyaluronic acid modified oral drug delivery system with mucoadhesiveness and macrophage-targeting for colitis treatment10.1016/j.carbpol.2023.120884 ↗
43. Inulin diet uncovers complex diet-microbiota-immune cell interactions remodeling the gut epithelium10.1186/s40168-023-01520-2 ↗
44. Colonic bacterial metabolites and human health10.1016/j.mib.2013.07.002 ↗
45. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome10.1126/scitranslmed.aap8914 ↗
46. Oral delivery of pterostilbene by l-arginine-mediated "nano-bomb" carrier for the treatment of ulcerative colitis10.2147/IJN.S347506 ↗
47. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon10.1016/j.cmet.2011.02.018 ↗
48. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis10.1016/j.cmet.2023.03.003 ↗
49. Inflammatory responses induced by the monophasic variant of salmonella typhimurium in pigs play a role in the high shedder phenotype and fecal microbiota composition10.1128/msystems.00852-22 ↗
50. Amino acid metabolism and signalling pathways: potential targets in the control of infection and immunity10.1038/s41430-021-00943-0 ↗
51. Glutamine reliance in cell metabolism10.1038/s12276-020-00504-8 ↗
52. Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms10.1038/s41467-022-34667-x ↗
53. The microbial metabolites, short-chain fatty acids, regulate colonic treg cell homeostasis10.1126/science.1241165 ↗
54. Comprehensive detection of genes causing a phenotype using phenotype sequencing and pathway analysis10.1371/journal.pone.0088072 ↗